Financial Ratios

BROOKS LABORATORIES LTD.

NSE : BROOKSBSE : 533543ISIN CODE : INE650L01011Industry : Pharmaceuticals & DrugsHouse : Private
BSE98.67-2.01 (-2 %)
PREV CLOSE ( ) 100.68
OPEN PRICE ( ) 98.67
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 851
TODAY'S LOW / HIGH ( )98.67 98.67
52 WK LOW / HIGH ( )56.5 185.15
NSE98.80-1.2 (-1.2 %)
PREV CLOSE( ) 100.00
OPEN PRICE ( ) 0.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3154
TODAY'S LOW / HIGH( ) 98.80 99.05
52 WK LOW / HIGH ( )56.95 185.7
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)-3.320.27-6.31-9.87-9.15
   CEPS(Rs)-2.600.86-3.41-7.11-4.24
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)22.9826.3125.9939.8461.53
   Tax Rate(%)0.000.00-84.79-80.380.95
Margin Ratios
   Core EBITDA Margin(%)-10.472.441.22-5.63-15.20
   EBIT Margin(%)-13.371.74-6.71-14.58-21.78
   Pre Tax Margin(%)-14.750.87-10.92-19.39-27.16
   PAT Margin (%)-14.750.87-20.17-34.98-26.90
   Cash Profit Margin (%)-11.662.80-10.99-25.44-15.09
Performance Ratios
   ROA(%)-8.360.68-12.43-15.48-9.29
   ROE(%)-13.451.03-19.17-24.62-13.83
   ROCE(%)-11.221.87-5.24-7.77-8.60
   Asset Turnover(x)0.570.780.620.440.35
   Sales/Fixed Asset(x)2.543.781.020.530.42
   Working Capital/Sales(x)-10.2649.00-224.44-8.84-3.52
Efficiency Ratios
   Fixed Capital/Sales(x)0.390.260.981.902.40
   Receivable days91.3258.3959.4070.6671.64
   Inventory Days91.6568.6861.7762.4071.18
   Payable days221.56144.92150.71207.31248.90
Valuation Parameters
   PER(x)0.00266.670.000.000.00
   PCE(x)-23.8983.33-18.07-2.13-10.38
   Price/Book(x)2.722.762.390.380.87
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)2.872.382.080.912.07
   EV/Core EBITDA(x)-27.9064.9184.53-17.96-20.79
   EV/EBIT(x)-21.45137.15-31.04-6.21-9.52
   EV/CE(x)1.721.771.730.400.73
   M Cap / Sales2.782.331.990.541.57
Growth Ratio
   Net Sales Growth(%)-27.84-0.4010.8926.64-1.22
   Core EBITDA Growth(%)-302.2448.12154.1935.9136.84
   EBIT Growth(%)-655.85125.7548.9615.2020.78
   PAT Growth(%)-1329.91104.2736.05-64.64-7.19
   EPS Growth(%)-1329.91104.2736.05-7.88-7.19
Financial Stability Ratios
   Total Debt/Equity(x)0.100.080.130.270.31
   Current Ratio(x)0.841.040.990.830.67
   Quick Ratio(x)0.490.580.500.530.46
   Interest Cover(x)-9.681.99-1.60-3.03-4.05
   Total Debt/Mcap(x)0.040.030.050.710.36

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.